These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21386843)

  • 1. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
    Farace F; Gross-Goupil M; Tournay E; Taylor M; Vimond N; Jacques N; Billiot F; Mauguen A; Hill C; Escudier B
    Br J Cancer; 2011 Mar; 104(7):1144-50. PubMed ID: 21386843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies.
    Taylor M; Rössler J; Geoerger B; Laplanche A; Hartmann O; Vassal G; Farace F
    Clin Cancer Res; 2009 Jul; 15(14):4561-71. PubMed ID: 19605404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.
    Massard C; Borget I; Le Deley MC; Taylor M; Gomez-Roca C; Soria JC; Farace F
    Eur J Cancer; 2012 Jun; 48(9):1354-62. PubMed ID: 22370181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
    Vroling L; van der Veldt AA; de Haas RR; Haanen JB; Schuurhuis GJ; Kuik DJ; van Cruijsen H; Verheul HM; van den Eertwegh AJ; Hoekman K; Boven E; van Hinsbergh VW; Broxterman HJ
    Angiogenesis; 2009; 12(1):69-79. PubMed ID: 19212818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
    Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
    Gruenwald V; Beutel G; Schuch-Jantsch S; Reuter C; Ivanyi P; Ganser A; Haubitz M
    BMC Cancer; 2010 Dec; 10():695. PubMed ID: 21194438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol.
    Schmidt-Lucke C; Fichtlscherer S; Aicher A; Tschöpe C; Schultheiss HP; Zeiher AM; Dimmeler S
    PLoS One; 2010 Nov; 5(11):e13790. PubMed ID: 21072182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of circulating progenitor cells in left ventricular dysfunction.
    Boilson BA; Larsen K; Harbuzariu A; Delacroix S; Korinek J; Froehlich H; Bailey KR; Scott CG; Shapiro BP; Boerrigter G; Chen HH; Redfield MM; Burnett JC; Simari RD
    Circ Heart Fail; 2010 Sep; 3(5):635-42. PubMed ID: 20573992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent hypermulticolor monitoring of CD31, CD34, CD45 and CD146 endothelial progenitor cell markers for acute myocardial infarction.
    Shim Y; Nam MH; Hyuk SW; Yoon SY; Song JM
    Anal Chim Acta; 2015 Jan; 853():501-507. PubMed ID: 25467496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated Inflammatory Parameter Levels Negatively Impact Populations of Circulating Stem Cells (CD133+), Early Endothelial Progenitor Cells (CD133+/VEGFR2+), and Fibroblast Growth Factor in Stroke Patients.
    Golab-Janowska M; Paczkowska E; Machalinski B; Kotlega D; Meller A; Safranow K; Wankowicz P; Nowacki P
    Curr Neurovasc Res; 2019; 16(1):19-26. PubMed ID: 30706812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
    Niinivirta M; Georganaki M; Enblad G; Lindskog C; Dimberg A; Ullenhag GJ
    BMC Cancer; 2020 Apr; 20(1):339. PubMed ID: 32321460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating hematopoietic and endothelial progenitor cells in newborn infants: effects of gestational age, postnatal age and clinical stress in the first 3 weeks of life.
    Bui KC; Weems M; Biniwale M; George AA; Zielinska E; Azen CG; Durand M; Abdel-Azim H
    Early Hum Dev; 2013 Jun; 89(6):411-8. PubMed ID: 23312395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
    Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
    Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
    Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evaluation of circulating endothelial progenitor cells and related angiogenic markers as prognostic factors in soft-tissue tumors.
    Karampinis I; Joas E; Dreyer A; Ronellenfitsch U; Jakob J; Hohenberger P; Nowak K
    Eur J Surg Oncol; 2018 Apr; 44(4):496-501. PubMed ID: 29397265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells.
    Brunner S; Theiss HD; Murr A; Negele T; Franz WM
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1670-5. PubMed ID: 17911347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
    Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
    BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Zhou X; Fu G; Zu X; Xu Z; Li HT; D'souza A; Tulpule V; Quinn DI; Bhowmick NA; Weisenberger DJ; Liang G; Chen J
    Urol Oncol; 2022 Jan; 40(1):12.e13-12.e22. PubMed ID: 34454823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.